The Approval Process in Action

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

For news on how catalysts affect specific stocks, read the updated Life Sciences Report Watchlist.

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal
Source: Streetwise Reports (04/08/2025)

Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential.

Lending Innovator Outpaces Market Trends in United States
Source: Streetwise Reports (04/08/2025)

High interest rates and prices have sidelined many would-be homebuyers in recent years, but better days may finally be ahead for many of them. One company in particular is outpacing the industry in loan origination.

Biotech Company Finds High-Impact Alzheimer's Therapy in Europe
Source: Streetwise Reports (04/07/2025)

Anavex Life Sciences Corp. (AVXL:NASDAQ) earned positive analyst coverage following new long-term data for blarcamesine in early Alzheimer's disease. Experts pointed to safety, durability, and potential approval pathways. Read more about what they said.

Immunotherapy Company Finds Rare Cancer Breakthrough in U.S.
Source: Streetwise Reports (04/07/2025)

OS Therapies Inc. (OSTX:NYSEAMERICAN) announced that its lead drug OST-HER2 was granted Orphan Drug Designation by the FDA for osteosarcoma. Read how the designation could accelerate development and create new investor interest.

Uranium Explorer Unites Assets in Nevada for High-Grade Breakthrough
Source: Streetwise Reports (04/07/2025)

Aero Energy Ltd. (AERO:TSXV; AAUGF:OTC; UU3:FRA) advances its uranium ambitions with a high-impact merger and drill-ready targets in Canada and Nevada. Read more about the company's next steps and why one newsletter writer is taking notice.